T-alpha-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-11 and is reviewed periodically as new material appears.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
== Toxicity == Buformin was withdrawn from the market in many countries due to an elevated risk of causing lactic acidosis (although not the US, where it was never sold). Buformin is still available and prescribed in Romania (timed release Silubin Retard is sold by Zentiva), Hungary, Taiwan and Japan (sold by Nichi-Iko Pharmaceutical Co., Ltd as "DIBETOS" tablets, each containing 50 mg buformin hydrochloride). The lactic acidosis occurred only in patients with a buformin plasma level of greater than 0.60 μg/mL and was rare in patients with normal renal function. In one report, the toxic oral dose was 329 ± 30 mg/day in 24 patients who developed lactic acidosis on buformin. Another group of 24 patients on 258 ± 25 mg/day did not develop lactic acidosis on buformin.
It is the most popular type of soy sauce in Kyushu region of Japan, which is famous for sweet foods. In some cases, it is more common to find amakuchi shoyu than koikuchi shoyu in Kyushu. Newer varieties of Japanese soy sauce include:
== Stable isotope mass spectrometry == Stable isotope mass spectrometry is conducted in the Department of Geography, and was recently used by the Landmark Trust to determine very precisely the age of the timber from Llwyn Celyn farmhouse to the year 1420.
Famous Russian surgeon and scientist N. I. Pirogov was embalmed after his death in 1881. He was embalmed using the technique he himself developed. His body rests in a church in Vinnitsa, Ukraine. In contrast to the corpse of Lenin, which undergoes thorough maintenance in a special underground clinic twice a week, the body of Pirogov rests untouched and unchanging – reportedly only dust has to be brushed off of it. It rests at room temperature in a glass-lid coffin (while Lenin's body is preserved at a constant low temperature). Abraham Lincoln was embalmed after his assassination in 1865. To prevent anyone stealing Lincoln's body, Lincoln's eldest son Robert called for Lincoln's exhumation in 1901 to be buried in a concrete vault in the burial room of his tomb in Springfield, Illinois. Fearing that his body would have been stolen in the interim, Lincoln's coffin was opened, and his features were still recognizable, 36 years after his death. Rosalia Lombardo, who died at age one on 6 December 1920, was one of the last corpses to be interred in the Capuchin catacombs of Palermo, Sicily before the local authorities banned the practice. Nicknamed the 'Sleeping Beauty', Rosalia's body is still perfectly intact. Embalmed by Alfredo Salafia, she is in a glass case, looking very much like a surreal doll. Eva Perón was embalmed by Dr. Pedro Ara, as ordered by her husband Juan Perón. The body was preserved to look like it was in a sleep-like state.
10 mm (0.4 in) – it has well-defined gill arches and has a thin ventral finfold 21 mm (0.8 in) – dorsal and pelvic fin buds appear 33 mm (1.3 in) – embryo has protruding eyes and well-developed gill filaments 43 mm (1.7 in) – it has lost its translucency and develops slits in the egg case, allowing fluid exchange from surrounding seawater and the interior 58 mm (2.3 in) – the finfold starts to decay 66 mm (2.6 in) – the finfold and gill filaments are reduced or absent 74 mm (2.9 in) – external appearance is complete but yolk sac is still being absorbed 100–110 mm (3.9–4.3 in) – hatching
Sources: en.wikipedia.org
After the riots, the controversial New Economic Policy was launched by Prime Minister Tun Abdul Razak, trying to increase the share of the economy held by the bumiputera. Under Prime Minister Mahathir Mohamad there was a period of rapid economic growth and urbanisation beginning in the 1980s. The economy shifted from being agriculturally based to one based on manufacturing and industry. Numerous mega-projects were completed, such as the Petronas Towers, the North–South Expressway, the Multimedia Super Corridor, and the new federal administrative capital of Putrajaya. In the late 1990s, the Asian financial crisis impacted the country, nearly causing their currency, stock, and property markets to crash; however, they later recovered. The 1MDB scandal was a major global corruption scandal that implicated then-Prime Minister Najib Razak in 2015. The scandal contributed to the first change in the ruling political party since independence in the 2018 general election. In the 2020s, the country was gripped by a political crisis that coincided with health and economic crises caused by the COVID-19 pandemic. This was then followed by an earlier general election in November 2022, which resulted in the first hung parliament in the nation's history. On 24 November 2022, Anwar Ibrahim was sworn in as the 10th Prime Minister of Malaysia, leading a grand coalition government.
Dopamine β-hydroxylase catalyzes the hydroxylation of not only dopamine but also other phenylethylamine derivatives when available. The minimum requirement seems to be the phenylethylamine skeleton: a benzene ring with a two-carbon side chain that terminates in an amino group.
=== Gene mutations === Several gene mutations have been identified in patients with camptocormia. These include the RYR1 gene in axial myopathy, the DMPK gene in myotonic dystrophy, and genes related to dysferlinopathy and Parkinson's disease. These genes could serve as targets for gene therapy to treat the condition in the years to come.
When Eddy first met Quimby in Portland in October 1862, she had to be helped up the stairs to his consulting rooms. She spoke highly of him the following month in a letter to the Portland Evening Courier: "This truth which he opposes to the error of giving intelligence to matter and placing pain where it never placed itself ... changes the currents of the system to their normal action ..." In a second letter she offered to supply quotations from Quimby's "theory of Christ (not Jesus)." Between then and May 1864, Eddy returned to see Quimby several times, staying for weeks in Portland and visiting him daily. She wrote to him regularly, and composed a sonnet for him, "Mid light of science sits the sage profound." Eddy first used mental healing on a patient in March 1864, when one of Quimby's patients in Portland, Mary Ann Jarvis, suffered a relapse when she returned home to Warren, Maine. Eddy stayed with her for two months, giving Jarvis mental healing to ease a breathing problem, and writing to Quimby six times for absent treatment for herself. She called the latter "angel visits"; in one of her letters to Quimby, she said that she had seen him in her room. In April she gave a public lecture in Warren, contrasting mental healing with Spiritualism, entitled: "P. P. Quimby's Spiritual Science healing disease, as opposed to Deism or Rochester Rapping Spiritualism."
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.